Demyelination during anti‐tumour necrosis factor therapy for psoriasis. (21st February 2018)

• Record Type: Journal Article
• Authors: Boggs, J. M. E.; Barnes, L.
• Is Part Of: Clinical and experimental dermatology. Volume 43:Number 5(2018)
• Page Start: 577
• Page End: 578
• Publication Date: 2018-02-21
• Subjects: Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/ced.13412
• Languages: English
• ISSNs: 0307-6938

Abstract

Summary: Anti‐tumour necrosis factor (anti‐TNF) therapies have been associated with neurological complications, including in rare cases demyelinating disease. It is currently unknown whether patients who have received more than one immunosuppressive agent or anti‐TNF have a greater risk of demyelination. We report the case of a 37‐year‐old woman with psoriasis who presented with an acute episode of demyelination while on anti‐TNF therapy. This case was complicated by the fact that progressive multifocal leukoencephalopathy was considered the likely diagnosis initially and was only definitively excluded by brain biopsy. This case demonstrates the difficulty establishing the correct diagnosis in patients with atypical presentations on immunomodulating therapies. We present this rare case of demyelination in a patient who received multiple immunosuppressive therapies to highlight this challenging clinical situation and discuss management with a literature review.